Format

Send to

Choose Destination
J Allergy Clin Immunol. 2015 Feb;135(2):551-3. doi: 10.1016/j.jaci.2014.12.1867.

Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation.

Author information

1
Dermatology, St James's Hospital, Dublin, Ireland.
2
Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom.
3
National Children's Research Centre, Our Lady's Children's Hospital, Dublin, Ireland.
4
Immunology, St James's Hospital, Dublin, Ireland.
5
Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom. Electronic address: irvinea@tcd.ie.
6
Dermatology, St James's Hospital, Dublin, Ireland; National Children's Research Centre, Our Lady's Children's Hospital, Dublin, Ireland; Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland. Electronic address: desa.lilic@newcastle.ac.uk.
PMID:
25662309
DOI:
10.1016/j.jaci.2014.12.1867
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center